| Jan 16, 2026 |
Jan 20, 2026 |
EVNIN LUKE
|
Director |
Sell |
48.1
|
-38,782
|
-1.76%
|
✓
|
$20.9K |
| Jan 13, 2026 |
Jan 15, 2026 |
EVNIN LUKE
|
Director |
Sell |
38.8
|
-111,227
|
-4.82%
|
✓
|
$61.8K |
| Jan 8, 2026 |
Jan 12, 2026 |
EVNIN LUKE
|
Director |
Sell |
38.8
|
-91,374
|
-3.81%
|
✓
|
$53.5K |
| Jan 5, 2026 |
Jan 7, 2026 |
EVNIN LUKE
|
Director |
Sell |
44.4
|
-71,054
|
-2.87%
|
✓
|
$45.9K |
| Dec 30, 2025 |
Jan 2, 2026 |
EVNIN LUKE
|
Director |
Sell |
40.6
|
-78,377
|
-3.07%
|
✓
|
$48.4K |
| Dec 22, 2025 |
Dec 29, 2025 |
EVNIN LUKE
|
Director |
Sell |
26.3
|
-291,283
|
-10.25%
|
✓
|
$185.2K |
| Dec 15, 2025 |
Dec 17, 2025 |
EVNIN LUKE
|
Director |
Sell |
45.0
|
-48,171
|
-1.67%
|
✓
|
$52K |
| Dec 10, 2025 |
Dec 12, 2025 |
EVNIN LUKE
|
Director |
Sell |
41.3
|
-82,971
|
-2.79%
|
✓
|
$88.6K |
| Dec 5, 2025 |
Dec 9, 2025 |
EVNIN LUKE
|
Director |
Sell |
37.5
|
-95,179
|
-3.10%
|
✓
|
$94.8K |
| Dec 2, 2025 |
Dec 4, 2025 |
EVNIN LUKE
|
Director |
Sell |
37.5
|
-128,185
|
-4.01%
|
✓
|
$117.6K |
| Dec 2, 2025 |
Dec 4, 2025 |
MPM BioVentures 2014, L.P.
|
Other |
Sell |
37.5
|
-199,732
|
-4.01%
|
✓
|
$183.3K |
| Dec 2, 2025 |
Dec 4, 2025 |
GADICKE ANSBERT
|
Other |
Sell |
37.5
|
-199,732
|
-4.01%
|
✓
|
$183.3K |
| Nov 26, 2025 |
Dec 1, 2025 |
EVNIN LUKE
|
Director |
Sell |
41.3
|
-91,088
|
-2.77%
|
✓
|
$87.8K |
| Nov 26, 2025 |
Dec 1, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
41.3
|
-141,927
|
-2.77%
|
✓
|
$136.9K |
| Nov 26, 2025 |
Dec 1, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
41.3
|
-141,927
|
-2.77%
|
✓
|
$136.9K |
| Nov 21, 2025 |
Nov 25, 2025 |
EVNIN LUKE
|
Director |
Sell |
37.5
|
-125,576
|
-3.68%
|
✓
|
$115.2K |
| Nov 21, 2025 |
Nov 25, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
37.5
|
-195,666
|
-3.68%
|
✓
|
$179.6K |
| Nov 21, 2025 |
Nov 25, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
37.5
|
-195,666
|
-3.68%
|
✓
|
$179.6K |
| Nov 18, 2025 |
Nov 20, 2025 |
EVNIN LUKE
|
Director |
Sell |
41.3
|
-102,753
|
-2.92%
|
✓
|
$94.9K |
| Nov 18, 2025 |
Nov 20, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
41.3
|
-160,103
|
-2.92%
|
✓
|
$147.9K |
| Nov 18, 2025 |
Nov 20, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
41.3
|
-160,103
|
-2.92%
|
✓
|
$147.9K |
| Nov 13, 2025 |
Nov 17, 2025 |
EVNIN LUKE
|
Director |
Sell |
37.5
|
-134,553
|
-3.69%
|
✓
|
$128.8K |
| Nov 13, 2025 |
Nov 17, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
37.5
|
-209,652
|
-3.68%
|
✓
|
$200.7K |
| Nov 13, 2025 |
Nov 17, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
37.5
|
-209,652
|
-3.68%
|
✓
|
$200.7K |
| Nov 7, 2025 |
Nov 12, 2025 |
EVNIN LUKE
|
Director |
Sell |
37.5
|
-137,041
|
-3.62%
|
✓
|
$154.9K |
| Nov 7, 2025 |
Nov 12, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
37.5
|
-213,529
|
-3.62%
|
✓
|
$241.3K |
| Nov 7, 2025 |
Nov 12, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
37.5
|
-213,529
|
-3.62%
|
✓
|
$241.3K |
| Nov 4, 2025 |
Nov 6, 2025 |
EVNIN LUKE
|
Director |
Sell |
37.5
|
-155,885
|
-3.95%
|
✓
|
$189.8K |
| Nov 4, 2025 |
Nov 6, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
35.0
|
-242,890
|
-3.95%
|
✓
|
$295.8K |
| Nov 4, 2025 |
Nov 6, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
35.0
|
-242,890
|
-3.95%
|
✓
|
$295.8K |
| Oct 30, 2025 |
Nov 3, 2025 |
EVNIN LUKE
|
Director |
Sell |
35.0
|
-189,356
|
-4.58%
|
✓
|
$251.3K |
| Oct 30, 2025 |
Nov 3, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
35.0
|
-295,043
|
-4.58%
|
✓
|
$391.6K |
| Oct 30, 2025 |
Nov 3, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
35.0
|
-295,043
|
-4.58%
|
✓
|
$391.6K |
| Oct 27, 2025 |
Oct 29, 2025 |
EVNIN LUKE
|
Director |
Sell |
35.0
|
-177,145
|
-4.11%
|
✓
|
$286.5K |
| Oct 27, 2025 |
Oct 29, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
35.0
|
-276,017
|
-4.11%
|
✓
|
$446.4K |
| Oct 27, 2025 |
Oct 29, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
35.0
|
-276,017
|
-4.11%
|
✓
|
$446.4K |
| Jun 12, 2025 |
Jun 13, 2025 |
Lazarus Alon
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 12, 2025 |
Jun 13, 2025 |
Morrison Briggs
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 12, 2025 |
Jun 13, 2025 |
Chatterjee Meeta
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 12, 2025 |
Jun 13, 2025 |
EVNIN LUKE
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 12, 2025 |
Jun 13, 2025 |
Sherman Michael A.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 11, 2025 |
Jun 13, 2025 |
Singhal Anil K.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 12, 2025 |
Jun 13, 2025 |
Atkins Michael B.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 12, 2025 |
May 14, 2025 |
RA CAPITAL MANAGEMENT, L.P.
|
Director |
Buy |
92.5
|
+536,426
|
9.41%
|
✗
|
$487.2K |
| May 1, 2025 |
May 2, 2025 |
Bloom Steven H.
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Mar 27, 2025 |
Apr 30, 2025 |
MPM BioVentures 2014, L.P.
|
10% Owner |
Sell |
52.5
|
-1,963
|
-0.06%
|
✗
|
$2.1K |
| Mar 27, 2025 |
Apr 30, 2025 |
EVNIN LUKE
|
Director |
Sell |
52.5
|
-2,425
|
-0.06%
|
✗
|
$2.5K |
| Mar 27, 2025 |
Apr 30, 2025 |
GADICKE ANSBERT
|
10% Owner |
Sell |
52.5
|
-4,386
|
-0.07%
|
✗
|
$4.6K |
|
Apr 18, 2025 |
Bloom Steven H.
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 19, 2025 |
Feb 21, 2025 |
Singhal Anil K.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Feb 21, 2025 |
Singhal Anil K.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2025 |
Jan 6, 2025 |
Lubman Ellen
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2025 |
Jan 6, 2025 |
Trost Timothy W.
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2025 |
Jan 6, 2025 |
Isaacs Randi
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2025 |
Jan 6, 2025 |
Karunatilake Chulani
|
Chief Technology Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2025 |
Jan 6, 2025 |
HICKLIN DANIEL J
|
Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 24, 2024 |
May 24, 2024 |
RA CAPITAL MANAGEMENT, L.P.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 24, 2024 |
May 24, 2024 |
DiRocco Derek
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 24, 2024 |
May 24, 2024 |
Morrison Briggs
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 24, 2024 |
May 24, 2024 |
Atkins Michael B.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 24, 2024 |
May 24, 2024 |
Chatterjee Meeta
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 24, 2024 |
May 24, 2024 |
Sherman Michael A.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 24, 2024 |
May 24, 2024 |
EVNIN LUKE
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 24, 2024 |
May 24, 2024 |
Lazarus Alon
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 4, 2024 |
Jan 4, 2024 |
Atkins Michael B.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Jan 4, 2024 |
Atkins Michael B.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2024 |
Jan 4, 2024 |
Trost Timothy W.
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2024 |
Jan 4, 2024 |
Lubman Ellen
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2024 |
Jan 4, 2024 |
Isaacs Randi
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2024 |
Jan 4, 2024 |
Karunatilake Chulani
|
Chief Technology Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2024 |
Jan 4, 2024 |
Seidel-Dugan Cynthia
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 2, 2024 |
Jan 4, 2024 |
HICKLIN DANIEL J
|
Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
RA CAPITAL MANAGEMENT, L.P.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Morrison Briggs
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
EVNIN LUKE
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Lazarus Alon
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
DiRocco Derek
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Chatterjee Meeta
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Sherman Michael A.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 6, 2023 |
Jan 10, 2023 |
RA CAPITAL MANAGEMENT, L.P.
|
Director |
Buy |
100.0
|
+1,853,000
|
48.15%
|
✗
|
$4.1M |
| Jan 3, 2023 |
Jan 9, 2023 |
HICKLIN DANIEL J
|
Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 9, 2023 |
Lubman Ellen
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 9, 2023 |
Seidel-Dugan Cynthia
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 9, 2023 |
Karunatilake Chulani
|
Chief Technology Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 9, 2023 |
Trost Timothy W.
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 9, 2023 |
Leonard Reid
|
COO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 3, 2023 |
Jan 9, 2023 |
Isaacs Randi
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 1, 2022 |
Jun 3, 2022 |
RA CAPITAL MANAGEMENT, L.P.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 1, 2022 |
Jun 3, 2022 |
EVNIN LUKE
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 1, 2022 |
Jun 3, 2022 |
DiRocco Derek
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 1, 2022 |
Jun 3, 2022 |
Morrison Briggs
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 1, 2022 |
Jun 3, 2022 |
Karunatilake Chulani
|
Chief Technology Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 1, 2022 |
Jun 3, 2022 |
Sherman Michael A.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 1, 2022 |
Jun 3, 2022 |
Lazarus Alon
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 1, 2022 |
Jun 3, 2022 |
Chatterjee Meeta
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 6, 2022 |
Jan 18, 2022 |
Isaacs Randi
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 6, 2022 |
Jan 18, 2022 |
Leonard Reid
|
COO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 6, 2022 |
Jan 18, 2022 |
Trost Timothy W.
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 6, 2022 |
Jan 18, 2022 |
HICKLIN DANIEL J
|
Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 6, 2022 |
Jan 18, 2022 |
Lubman Ellen
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |